Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.

Bristol buys into the frenzy, and VEGF bispecific value inflation continues.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Evopoint reveals intriguing but opaque first-in-human data for XNW27011.

As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.

The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.

But camizestrant’s use could depend on uptake of monitoring – for now.